Loading clinical trials...
Loading clinical trials...
The primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic ITP
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Rigel Pharmaceuticals
NCT06722235 · Immune Thrombocytopenic Purpura (ITP)
NCT04890041 · Primary Immune Thrombocytopenic Purpura
NCT04428255 · Primary Immune Thrombocytopenic Purpura
NCT07426107 · Immune Thrombocytopenic Purpura, Coronary Artery Disease
NCT07059910 · Immune Thrombocytopenic Purpura, Thyroid Disorders
Arizona Oncology Associates
Tucson, Arizona
Bleeding & Clotting Disorders Institute
Peoria, Illinois
Horizon Oncology Research, Inc
Lafayette, Indiana
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions